Back to Search
Start Over
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.
- Source :
-
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2015 Aug; Vol. 98 (2), pp. 127-34. Date of Electronic Publication: 2015 Jun 29. - Publication Year :
- 2015
-
Abstract
- Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).<br /> (© 2015 American Society for Clinical Pharmacology and Therapeutics.)
- Subjects :
- Biotransformation
Cytochrome P-450 CYP2C19 metabolism
Cytochrome P-450 CYP2D6 metabolism
Genotype
Humans
Patient Safety
Phenotype
Risk Assessment
Risk Factors
Selective Serotonin Reuptake Inhibitors adverse effects
Selective Serotonin Reuptake Inhibitors pharmacokinetics
Cytochrome P-450 CYP2C19 genetics
Cytochrome P-450 CYP2D6 genetics
Drug Dosage Calculations
Pharmacogenetics standards
Polymorphism, Genetic
Selective Serotonin Reuptake Inhibitors administration & dosage
Subjects
Details
- Language :
- English
- ISSN :
- 1532-6535
- Volume :
- 98
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Clinical pharmacology and therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 25974703
- Full Text :
- https://doi.org/10.1002/cpt.147